65 results about "Pestivirus" patented technology

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and may comprise a nucleoside analogue, or a salt or prodrug thereof. The compound of the present invention may be administered alone or in combination with another anti-hepatitis C, anti-flavivirus and/or anti-pestivirus agent.

The disclosed invention is a bicyclo[4.2.1]nonane and its pharmaceutically acceptable salt or prodrug, and its composition and method of use to treat Flaviviridae (Hepacivirus, Flavivirus, and Pestivirus) infections in a host, including animals, and especially humans.

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

The disclosed invention is a composition for and a method of treating Flaviviridae (Hepacivirus, Flavivirus, Pestivirus) infections, including BVDV and HCV, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.

Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein E^rns and at least another mutation in the coding sequence for N^pro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein E^rns in addition to the inactivation of the (hypothesized) immunomodulating activity residing in N^pro. Methods for attenuating pestiviruses such as BVDV, nucleic acids encoding the pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV, of the invention.

The invention relates to the field of nucleic acid amplification, particularly to quality control materials for use in viral RNA assays. It specifically relates to the construction of a recombinant Pestivirus by the identification of a region in the 3′NTR of the viral RNA genome where additional sequence elements can be stably inserted. Chimeric Pestivirus with sequence insertions in the 3′ nontranslated region (3′NTR) of the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3′NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.

The invention belongs to the technical fields of animal virology and molecular biology, and particularly relates to a pig atypical pestivirus RT-PCR detection specific primer, a kit and a detection method. The nucleotide sequences of the specific primer are as shown in SEQ ID NO:1 and SEQ ID NO:2; the kit comprises the primer, a Prime Script 1 step enzyme mixture, a 2*1 step buffer solution and nuclease-free water. The invention also discloses a method for detecting pig atypical pestivirus by using the specific primer or the kit. The primer provided by the invention has high specificity and sensitivity and can be used for detecting and identifying the pig atypical pestivirus from various clinical samples, so that prevention and control measures can be taken quickly and timely, and economic loss is reduced.

The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses.

The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines wherein said chimeric pestivirus comprises a bovine viral diarrhea virus which does not express its homologous Ems protein, further wherein said chimeric pestivirus expresses a heterologous Ems protein derived from another pestivirus, or a natural, synthetic or genetic variant of said heterologous Erns protein. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.

The present invention is directed to attenuated pestivirus mutants, which have a reduced ability to replicate as exhibited by a small plaque size. The mutations are in the 5′ nontranslated region of the viral genome. These mutant viruses are useful as live vaccines in the control of bovine viral diarrhea, border disease and classical swine fever.

The invention relates to a process for the recombinant production of a heterologous polypeptide of interest, comprising, (i) cultivation of a bacterial host cell which is transformed with an expression vector which comprises a nucleic acid molecule which codes for a fusion polypeptide, the fusion polypeptide comprising a derivative of an autoprotease N of Pestivirus, wherein at least one cysteine residue of the naturally occuring autoprotease N of Pestivirus is replaced by another amino acid residue, and a second polypeptide which is connected to the first polypeptide at the C-terminus of the first polypeptide in a manner such, that the second polypeptide is capable of being cleaved from the fusion polypeptide by the autoproteolytic activity of the first polypeptide, said second polypeptide being a heterologous polypeptide, wherein cultivation occurs under conditions which cause expression of the fusion polypeptide and formation of corresponding cytoplasmic inclusion bodies, (ii) isolation of the inclusion bodies from the host cell, (iii) solubilization of the isolated inclusion bodies, (iv) induction of autoproteolytic cleavage of the heterologous polypeptide of interest from the fusion polypeptide, and (v) isolation of the cleaved heterologous polypeptide of interest.

The invention relates to a rabbit pestivirus antibody rapid detection card and a preparation method thereof. The preparation method comprises the following concrete steps: (1) preparing an anti-rabbit-pestivirus VP60 monoclonal antibody, concretely performing immunization program, cell fusion, hybridomas screening and cloning, and antibody preparation and purification; and (2) preparing the rabbit pestivirus antibody rapid detection card, concretely decocting a colloidal gold solution, marking the anti-rabbit-pestivirus VP60 monoclonal antibody, processing a colloidal-gold pad, processing a sample pad, and determining C and T lines. The rabbit pestivirus antibody rapid detection card is capable of rapidly, sensitively and accurately detecting rabbit pestivirus antibody, and overcomes the problems that domestic rabbit pestivirus antibody detection mainly employs erythrocyte hemagglutination and ELISA detection.

This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from diseases characterized by hyperproliferating cells by administering pharmaceutical compositions comprising WNV or other virus including Flavivirus or Pestivirus capsid or other protein or a nucleic acid molecule encoding the same. Methods of identifying compounds which have anti-viral and/or anti-WNV and/or anti-Flavivirus and/or anti-Pestivirus capsid or other protein activity are disclosed. The invention also provides vaccine compositions comprising capsid or other proteins, or fragments thereof, or nucleic acids encoding same, from WNV or other virus including Flavivirus or Pestivirus and a pharmaceutically acceptable carrier. The invention also provides diagnostic methods and kits for identifying individuals exposed to WNV or other viruses including Flavivirus or Pestivirus.

The invention relates to the field of biological products, and specifically relates to a Pestivirus suis and streptococcus suis vaccine composition and a preparation method thereof. The composition includes Pestivirus suis and streptococcus suis antigens. The invention also relates to application of the vaccine composition to preparation of a composition for the prevention and / or treatment of diseases associated with Pestivirus suis and streptococcus suis, and infections caused by Pestivirus suis and streptococcus suis.

The present invention relates to a vaccine for protecting a piglet against diseases associated with a novel pestivirus. The vaccine commonly includes a pestivirus antigen and, optionally an adjuvant. Methods for protecting pigs against diseases associated with pestivirus, including but not limited to congenital tremors and methods of producing the pestivirus vaccine are also provided.